Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-02-13
2010-10-19
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07816496
ABSTRACT:
A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5981711 (1999-11-01), Zavada et al.
patent: WO 88/08854 (1988-11-01), None
patent: WO 93/18152 (1993-09-01), None
Anton et al., “Localized renal-cell carcinoma: detection of abnormal cells in peritumoral tissue. A cytophotometry and immunocytochemistry study,”World J. Urol., 13(3): 149-152 (1995).
Costa et al., “MN Protein Immunolocalization in Uterine Cervix Carcinoma With Glandular Differentiation—A Clinicopathologic Study of a New Cancer-specific Biomarker,”International Journal of Surgical Pathology, 3(2): 73-82 (1995).
Divgi et al., “Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250,”European Journal of Nuclear Medicine, 19(8): 578 (Abstract 121-3) (Aug. 23, 1992).
Divgi et al., “Radioimmunotherapy (RIT) with I-131 Monoclonal Antibody (Mab) G250 in Metastatic Renal Cancer,”Proceedings of the 41st Annual Meeting, 35(5): 101P (Abstract #401) (May 1994).
Divgi et al., “Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer,”J. Nucl. Med., 36 (5 Suppl.): 913P (Abstract 956; May 1995).
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer,”PNAS(USA), 85: 8998-9002 (Dec. 1988).
Frosch et al., “Cloning and characterisation of an immunodominant major surface antigen of Echinococcus multilocularis,”Molecular and Biochemical Prasitology, 48: 121-130 (1991).
Kranenborg et al., “Development and Characterization of Anti-Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,”Cancer Res., 55 (23 Suppl.) 5864s-5867s (1995).
Kurth et al., “Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies,”Prostate, 6(4): 451 (Abstract) (1985).
Liao et al., “Identification of the MN /CA9 Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney,”Cancer Research, 57: 2827-2831 (Jul. 15, 1997).
Luner et al., “Monoclonal Antibodies to Kidney and Tumor-associated Surface Antigens of Human Renal Cell Carcinoma,”Cancer Res., 46(11): 5816-5820 (1986).
Moon et al., “A Highly Restricted Antigen for Renal Cell Carcinoma Defined by a Monoclonal Antibody,”Hybridoma, 4(2): 163-172 (1985).
Murakami et al., “MN/CA9 gene expression as a potential biomarker in renal cell carcinoma,”BJU International, 83: 743-747 (1999).
Oosterwijk and Debruyne, “Radiolabeled monoclonal antibody G250 in renal-cell carcinoma,”World Journal of Urology, 13: 186-190 (1995).
Oosterwijk et al., “Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and Other Malignancies,”Prostate, 6(4): 451-452 (Abstract) (1985).
Oosterwijk et al., “Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens—Application in the Diagnosis of Renal Cell Carcinoma,”American Journal of Pathology, 123(2): 301-309 (May 1986).
Oosterwijk et al., “Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney,”Int. J. Cancer, 38: 489-494 (1986).
Oosterwijk et al., “Relationship between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma,”Int. J. Cancer, 42: 703-708 (1988).
Oosterwijk et al., “Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma,”The Journal of Histochemistry and Cytochemistry, 38(3): 385-392 (1990).
Oosterwijk et al., “Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250,”Journal of Clinical Oncology, 11(4): 738-750 (Apr. 1993).
Oosterwijk et al., “The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma,”Seminars in Oncology, 22(1): 34-41 (Feb. 1995).
Oosterwijk et al., “Molecular characterization of the Renal Cell Carcinoma-associated antigen G250,”Proceedings of the American Association for Cancer Research, 37: 461 (Abstract #3147) (Mar. 1996).
Opavsky et al., “Regulation of MN Expression,”Cell Biology International, 18(5): Abstract No. Mo-58 (1994).
Pastorek et al., “The Structure and Expression of MN Gene, Coding for a Tumor-Associated Protein p54/58N,”J. Cancer Res., Clin. Oncol., 119 (Suppl. 1) 10/113 (1993).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorek et al., “MN—A Novel Type of Oncoprotein,”Cell Biology International, 18(5): Abstract No. Mo-57 (1994).
Pastorekova et al., “A Novel Quasi-viral Agent, MaTu, Is a Two-Component System,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Transformation of Mammalian Cells by MN Oncogene,”Cell Biology International, 18(5): Abstract No. Mo-56 (1994).
Stanbridge et al., “Specific Chromosome Loss Associated with the Expression of Tumorigenicity in Human Cell Hybrids,”Somatic Cell Genetics, 7(6): 699-712 (1981).
Stanbridge et al., “Human Cell Hybrids: Analysis of Transformation and Tumorigenicity,”Science, 215: 252-259 (Jan. 15, 1982).
Surfus et al., “Renal Cell Human-Mouse Chimeric Antibody G250 Mediates Antibody Dependent Cellular Cytotoxicity (ADCC),”Biological Abstracts, 47(9): 161224 (1995).
Tweedie and Edwards, “Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies,”Biochemical Genentics, 27(1/2): 17-30 (1989).
Uemura et al., “Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250,”Int. J. Cancer, 56: 609-614 (1994.
Uemura et al., “Vaccination with Anti-Idiotype Antibodies Mimicking a Renal Cell Carcinoma-Associated Antigen Induces Tumor Immunity,”Int. J. Cancer, 58: 555-561 (1994).
Uemura et al., “Immunization with Anti-Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal-Cell Carcinoma-Associated Antigen G250 Induces Specific Cellular Immune Responses,”Int. J. Cancer, 59: 802-807 (1994).
Uemura et al., “Anti-tumor effects of vaccination with internal image anti-idotype monoclonal antibodies,”Biotherapy(Japan), 9(3): 294-295 (1995) (English Language Summary.
Uemura et al., “Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target,”J. Urology: 157(4 Supp): 377 (Abstract 1475) (Apr. 16, 1997).
van Dijk et al., “Induction
Pastorek Jaromir
Pastorekova Silvia
Zavada Jan
Aeder Sean E
Harland Joan C.
Institute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Shimei Barbara A.
LandOfFree
MN gene and protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN gene and protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN gene and protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170904